Novavax Inc. stock underperforms Wednesday when compared to competitors | news.google.com • |
Shah Capital Management Acquires 1,544,263 Shares of Novavax, Inc. (NASDAQ:NVAX) | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Why Novavax is Gaining Ground in COVID-19 Vaccine Race | zacks.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-08 | 2024-06 | 1.82 | 0.99 | -0.83 | -45.60% |
2024-05-10 | 2024-03 | -1.04 | -1.05 | -0.01 | -0.96% |
2024-02-28 | 2023-12 | -0.49 | -1.44 | -0.95 | -193.88% |
2023-11-09 | 2023-09 | -1.82 | -1.26 | 0.56 | 30.77% |
2023-08-08 | 2023-06 | -1.24 | 0.58 | 1.82 | 146.77% |
2023-05-09 | 2023-03 | -3.38 | -3.41 | -0.03 | -0.89% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-08 | B. Riley Securities | Upgrade | Neutral | Buy |
2023-05-09 | HC Wainwright & Co. | Upgrade | Buy | |
2023-02-28 | B. Riley Securities | Downgrade | Buy | Neutral |
2023-02-12 | HC Wainwright & Co. | Upgrade | Buy | |
2023-01-01 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-06-11 | ALTON GREGG H | Director | 10.47K | Conversion of Exercise of derivative security |
2024-06-11 | DOUGLAS RICHARD H | Director | 43.92K | Conversion of Exercise of derivative security |
2024-06-16 | DUBOVSKY FILIP | Officer | 66.61K | Sale |
2024-08-15 | KELLY JAMES PATRICK | Chief Financial Officer | 14.43K | Conversion of Exercise of derivative security |
2024-06-11 | KING RACHEL K | Director | 18.92K | Conversion of Exercise of derivative security |
2024-06-11 | MCGLYNN MARGARET G | Director | 10.47K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | State Street Corporation | 11.68M | 86.78M | 12.37% |
2023-06-29 | Vanguard Group Inc | 10.57M | 78.55M | 11.20% |
2023-06-29 | Blackrock Inc. | 6.99M | 51.97M | 7.41% |
2023-09-29 | Shah Capital Management | 6.33M | 45.83M | 6.71% |
2023-06-29 | Bank of America Corporation | 2.18M | 16.23M | 2.31% |
2023-06-29 | Morgan Stanley | 2.08M | 15.46M | 2.20% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 9.38M | 75.07M | 9.94% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 2.64M | 19.60M | 2.79% |
2023-06-29 | Vanguard Small-Cap Index Fund | 2.23M | 16.56M | 2.36% |
2023-08-30 | iShares Russell 2000 ETF | 2.01M | 16.10M | 2.13% |
2023-06-29 | Vanguard Small-Cap Growth Index Fund | 1.28M | 9.48M | 1.35% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.21M | 8.98M | 1.28% |
Split | Date |
---|---|
1 : 20 | 2019-05-10 |
-
NVAX reports next week, it is going to be the first big and positive earnings.
-
Let’s go! mRNA is up 7%
-
Canada approved NVAX and has committed to purchase 52 million doses of the vaccine, with an option to buy up to 24 million doses more.
-
German government said on Monday they expect deliveries of the Novavax NVAX.O COVID-19 vaccine Nuvaxovid to begin over the course of this week.
-
EU countries have ordered 27 million doses for the first quarter of this year, of a contract for 100 million vaccines and another 100 million optional.
-
$NVAX does anyone have info on $MRNA & $PFE shipments of their fully approved biologics Spikevax & Comirnaty? The HHS happened to archive that information the month before PFE’s was approved. The word is that they are not being distributed widely because they come with liability for the companies and their “COVID-19” EUA shot injuries fall on FDA. Waiting for kiddo shot approvals (which likely won’t happen) so they have full immunity from actually caring for people.
I digress but I did reach out to HHS with no response.
-
Pressure being applied by holders worried about the pandemic being over - the Omicron variant is basically run its course in the US and UK - But it has not in other areas of the world and there is a huge potential for a new and stronger variant to appear - that is the emotion that is driving the stock - meaning essentially that nothing has appeared yet and sellers decided that the vaccination game is over - I say it is not over and that the guidance and manufacturing issues will be exhibited in the eps release - fundamentals will drive NVAX, not short term emotion from hysterical holders watching MRNA
-
I have to say one thing - given the closeness of the eps release, company principles have to be very careful about what they say - they are in a quiet period - so any information released has to already be in the public arena - the doubters (shorts) remain focused on manufacturing delays and constantly want to scare the longs into believing gloom and doom are coming - that just sets up a huge rally once the numbers are actually released - the stock price will jump very quickly on the numbers that get extrapolated by the analysts who follow the stock - sit tight and avoid all the negative noise - the overall market might have some headwinds but NVAX will move on its own merit
-
Unfortunately the CPI damaged the market enthusiasm and is holding back the potential upside move in NVAX that appears to be in place - I am fully expecting FDA approval before the end of the month - I don’t think this approval has been discounted in the stock, moreover I still believe that the shorts (LaurenM21) are holding fast for the FDA to be delayed - guidance from the company will move the stock - remember, it is not what has happened but what will happen - it may take somewhat longer, but hold this stock tightly as eps will explode during this coming year
-
-
-
NVAX is in a quiet period that precedes EPS release - so you will hear nothing from any principles or insiders at the company - the PR department cannot release any info or rebuttals at this time - I would think the stock will move higher into the eps release - but remember that the stock will only move on what will happen as opposed to what happened
-
The eps release and conference call will be the driver for the near term - but remember that the eps is about the 4Q 2021 and not what will be discussed to move the stock - that will be the guidance for the 1Q and beyond - LaurenM21 has no idea what is happening and is trying to scare you further - a believer in NVAX will see if the manufacturing and delivery schedule will occur - she acts like it will be devastating if something is delayed - I am of the faith that delivery will occur in 2022 and the stock will appreciate accordingly - a small company like NVAX is now growing up quickly and glitches will/do occur - hold the stock for the next 6 months and you will be rewarded immensely
-
One thing always happens is that gaps get filled - this morning one was created between $91 and $87 - so hold tight as that must be covered at some point
-
Amazing how the shorts come out when some bad news (whether actual or not) hits NVAX - today is rough due to this release as well as PFE not hitting numbers - BNTX went down early but now in recovery mode - NVAX will trace the same patterns - NVAX is not going to “0” as the doubters believe - in fact it will start recovering into the eps release - that day will be critical as I mentioned before - the FDA will approve, no doubts there as Israel has given the signal - the stock performance will take some time but the glitches have to be worked out, meaning manufacturing and delivery - selling now makes no sense as one has invested for what is about to happen, not what has happened
-
-
I have stated many times that the key for huge success in the NVAX model is making good on deliveries - and that would be expressed in the conf call coming up - I don’t think the real key is what has happened so far (which now appears, given today’s action, to be poor) but what they will project when giving guidance - it hurts to see the stock get pummeled but negative news concerning potential revenue always creates doubt - if long and a believer in the NVAX vaccination, one must stay the course and await the release and subsequent commentary - NVAX is now a “show me” situation and will be judged by revenue and eps - the hype from Covid is almost over and NVAX must transition with that - it has to look forward to how it can supplant competition
-
Novavax Inc. stock underperforms Wednesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Why Novavax is Gaining Ground in COVID-19 Vaccine Race
news.google.com • -
Novavax Inc. stock underperforms Monday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Monday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Monday when compared to competitors
news.google.com • -
(NVAX) Trading Report
news.google.com • -
Novavax Inc. stock outperforms competitors on strong trading day
news.google.com • -
Should You Buy Novavax Stock After This Regulatory Win?
news.google.com • -
Should You Buy Novavax Stock After This Regulatory Win?
news.google.com • -
Novavax Inc. stock underperforms Thursday when compared to competitors
news.google.com • -
Why Are Novavax Shares Trading Lower Today?
news.google.com • -
Novavax Inc. stock underperforms Wednesday when compared to competitors
news.google.com • -
Novavax, Inc. (NVAX) Baird 2024 Global Healthcare Conference (Transcript)
seekingalpha.com • -
Novavax to Participate in Upcoming September Conferences
prnewswire.com • -
Novavax: Staying Long Despite Coming Up Short In Q2
seekingalpha.com • -
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
marketbeat.com • -
Novavax, Inc. (NVAX) Q2 2024 Earnings Call Transcript
seekingalpha.com •